GE Profit Jumps 16%: Ahead of the Ticker

NEW YORK ( TheStreet) -- General Electric ( GE) reported a first-quarter profit increase of 16%, coming in line with analysts' expectations.

The company's results were driven by strong sales of oil and gas drilling equipment, as well as the $18.1 billion sale of its stake in NBCUniversal in February. That sale boosted profit by 4 cents a share, according to GE.

Since then, the company has annouced a $3.3 billion acquisition of Lufkin Industries ( LUFK) and accelerated share buybacks.

GE reported earnings of $3.53 billion, or 34 cents per share, compared with $3.03 billion, or 29 cents a share, in the same quarter a year ago.

Excluding items, the company said it earned 35 cents per share, meeting estimates.

Revenue beat expectations. The company reported revenue of $35 billion, compared to estimates of $34.51 billion.

The company also reported that its order backlog rose to $216 billion from $210 billion in the prior quarter.


Blackstone Group ( BX) is pulling out of its pursuit of Dell ( DELL).

In a letter to Dell's board, Blackstone attributed its withdrawal to Dell's slumping PC sales. Blackstone noted the 14% drop in PC shipments in the first quarter, its largest drop in the company's history, as well as Dell's weakening finances and the lower operating income forecast Dell has issued since Blackstone made its bid for the company. Dell revised its operating income projections for the current year to $3 billion from $3.7 billion.

The move comes less than a month after Blackstone announced a plan to top a buyout offer from CEO Michael Dell and a group of investors led by Silver Lake Partners for $24.4 billion, or $13.65 a share. Blackstone is pulling out of its plans without formally submitting a superior offer to the bid by Michael Dell and Silver Lake.


GlaxoSmithKline ( GSK) is being accused of paying off its rivals to delay launches of their versions of Glaxo's antidepressant drug Seroxat.

Britain's Office of Fair Trading alleges that Glaxo infringed upon competition laws through deals with several competitors over a cheaper version of Seroxat. The competition watchdog alleges that Glaxo made agreements with three generic drugmakers, Alpharma, Generics and Norton Healthcare, that paid the companies to delay launching the drug. The OFT says the moves is an abuse of Glaxo's dominant market position.

Glaxo denies the charges and said the company believes it acted according to the law. If the company is found guilty of the allegations, it could be fined up to 10% of its worldwide turnover.


The chatter on Main Street (a.k.a. Google, Yahoo! and other search sites) is always of interest to investors on Wall Street. Thus, each day, TheStreet compiles the stories that are trending on the Web, and highlights the news that could make stocks move.

-- Written by Brittany Umar.

Brittany joined TheStreet.com TV in November 2006 after completing a degree in Journalism and Media Studies at Rutgers College. Previously, Brittany interned at the local ABC affiliate in New York City WABC-TV 7 where she helped research and produce On Your Side, a popular consumer advocacy segment.

More from Stocks

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says